BIOMARIN PHARMACEUTICALInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
-$9.1M
Buys minus sales2026.06.02
Latest Form 416
Reporting entitiesNo buyer detected
No open-market buysDavis George Eric
$1.6MAutomated_Intelligence_Report :: BMRN
Algorithmic analysis of recent insider trading activity for BMRN reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 16 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $16.40M.
Market dynamics show a negative net capital flow of $9.11M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the most significant liquidity event was a divestment by Davis George Eric (Officer/Other), which accounts for a major share of the recent outflow. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of BMRN.
$16.40M
USD NOMINAL VALUE16
UNIQUE C-SUITE ENTITIES2026.06.02
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>When was the latest SEC Form 4 filed for BMRN?
The most recent insider transaction on record was filed on 2026.06.02. InsiderAlpha monitors EDGAR filings and updates this terminal as new Form 4 documents are published.
>How many corporate insiders are active in BMRN?
Our dataset currently tracks 16 distinct insiders with reported transactions for BMRN in the active reporting window.
>Is insider buying outweighing selling at BMRN?
Open-market selling volume ($9.11M) currently exceeds buying volume ($0.00M), indicating net liquidation by insiders.